Epidemiological study, pathologic evaluation and prognostic factors of colorectal mucinous adenocarcinoma VS non mucinous (About a series of 196 patients);Étude épidémiologique, anatomopathologique et évaluation des facteurs pronostiques des adénocarcinomes colorectaux mucineux vs non mucineux. (A propos d'une série de 196 patients)

Tunisie Medicale

Volumn 88, Issue 1, 2010, Pages 12-17

  Toumi, Amira Arfaoui ^a   Mahmoud, Lilia Kriaa Ben ^a   Khiari, Meriem ^a   Lahmer, Ahlem ^b   Gharbi, Lasaad ^b   Dhraïef, Monia ^b   Khalfallah, Tahar ^b   Mzabi, Sabeh Regaya ^a   Bouraouil, Saadia ^b  

^a Unité de Recherche M E S R S UR03ES04   (France)

^b MONGI SLIM HOSPITAL   (Tunisia)

Author keywords

Colorectal cancer; Epidemiology; Galectin 3; Immunohistochemistry; Mucinous adenocarcinoma

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER INVASION; COLORECTAL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PROGNOSIS; SEX RATIO;

EID: 77649266989     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hassan Brim, Pooneh Mokarram, Fakhraddin Naghibalhossaini et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008; 7:68.
2. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC cancer Base No.5, Version 2.0. Lyon: International Agency for Research on Cancer; 2004.
3. Thiravud Khuhaprema and Petcharin Srivatanakul. Colon and Rectum Cancer in Thailand: An Overview. Jpn J Clin Oncol 2008;38:237-243.
4. Peter Boyle, J S Langman. Epidemiology. ABC of colorectal cancer. Clinical review. BMJ 2000;321:805-808.
5. Cotran R.S, Kumar.V, Robbins. L. Pathologie : Bases morphologiques et physio-pathologiques des maladies Paris : Edition Française 1996:964-84.
6. Resistre des cancers Nord-Tunisie (1995-1998). Ministre de la santé publique. Secrétariat d'état à la recherche scientifique et de la technologie. Unité de recherche en épidémiologie des cancers en Tunisie.
7. Wenbo Du, Ph.D, James T.L, Jeannette Lee et al. Incidence and survival of mucinous adenocarcinoma of the colorectum : Apopulation-Based study from an Asian country. Dis Colon Rectum 2004; 47:78-85.
8. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921-9.
9. Lasser P, Mankarios H, Elias D, et al. Étude pronostique uni- et multifactorielle de 400 adénocarcinomes rectaux résé qués. J Chir (Paris) 1993; 130:57-65.
10. Horn A, Dahl O, Morild I. venous and neural invasion as predictors of recurrence in recta adenocarcinoma. Dis Colon Rectum 1991;34:798-804.
11. N. Arfa, I. Hamdani, L. Gharbi, et al. Survie et facteurs pronostiques des adénocarcinomes colorectaux : étude analytique uni- et multifactorielle de 150 cas. Annales de chirurgie 2006;131:104-11
12. Néel JC, Lasser P, Letessier E et al. Traitement chirurgical des cancers coliques après 75 ans. Étude d'une série de 240 patients. Chirurgie 1999;124:670-4.
13. Kanemitsu Y, Kato T, Hirai T et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003;46:160-7.
14. Malassagne B, Valleur P, Serra J, et al. Relationship of apical lymph node involvement to survival in resected colon carcinoma. Dis Colon Rectum 1993;36:645-53.
15. Elliot J. Coops, Sharon L. Manne, Neal J. Meropol and David S. Weinberg. Multiple behaviour risk factors for colorectal cancer and screening status. Cancer Epidemiol Biomarkers Prev 2007;16:510-6.
16. Akahani S, Nangia-Makker P, Inohara H, et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-6.
17. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2000;19:285-93.
18. Davidson PJ, Davis MJ, Patterson RJ, et al. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002;12:329-37.
19. Lin H-M, Pestell RG, Raz A, Kim HRC. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002;21:8001-10.
20. Sanjuan, X., Fernandez, P. L., Castells, A et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997;113:1906-15.
21. Schoeppner HL, Raz A, Ho SB and Bresalier RS. Expression of endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995;75:2818-26.
22. Nagy N, Legendre H, Engels O et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003;97:1849-58.
23. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.